
XIIDRA contains the active ingredient lifitegrast in an ophthalmic solution form at a concentration of 5%, designed as a lymphocyte function-associated antigen-1 (LFA-1) antagonist. The drug is formulated as a sterile, clear liquid for eye application, with each milliliter containing 50 mg of lifitegrast. Key inactive ingredients include sodium chloride, sodium phosphate dibasic anhydrous, and water for injection. It is a colorless to slightly brownish-yellow solution with a pH range of 7.0 to 8.0.